Alnylam Grants Calando a License to Develop and Commercialize an RNAi Therapeutic Product Target-Specific License for RNAi Intellectual Property Granted under Alnylam's InterfeRx(TM) Program
23 Aug 2006 -
Alnylam Pharmaceuticals, Inc. has granted Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research Corporation, an InterfeRx(TM) license to discover, develop, and commercialize an RNAi therapeutic utilizing a synthetic siRNA, together exclusively with Calando's proprietary delivery technology, that is directed towards a cancer target. As part of the agreement, Calando also has an
option to acquire an InterfeRx license for a second target gene. Detailed financial terms were not disclosed, but include upfront, annual, and milestone payments, and royalties on sales of any products covered by the licensing agreement.
Additional information
Alnylam Pharmaceuticals, Inc. Cambridge, United States of America
Top
Contact
Print version
PDF version
Send article
RSS-Feed